Oncology Central

Larotrectinib shows 93% response rate in pediatric cancer trial

A first-of-its-kind drug, termed larotrectinib, which targets TRK fusions has been demonstrated to be effective in 93% of pediatric patients tested. The drug is the first to be granted FDA breakthrough therapy designation for patients with a specific fusion of two genes in the cancer cell, no matter what cancer type.

TRK fusions occur in many types of cancer and whilst only small percentages occur in common adult cancers, this fusion occurs frequently in some rare pediatric cancers – such as infantile fibrosarcoma, cellular congenital mesoblastic nephroma and papillary thyroid cancer.

Findings from the trial were recently published in The Lancet Oncology. 

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.